The Institute for Next Generation Healthcare is building a multiscale integrated network of Lyme Disease (LymeMIND) that represents a unified, predictive model of Lyme disease.
LymeMIND is designed to enable a systems medicine approach to identify novel biomarkers and new therapeutic opportunities. Through our network of collaborators, we are able to interrogate the complex biology of samples collected from Lyme-affected individuals using molecular profiling technologies and applying advanced statistical and machine learning approaches to move rapidly from “Big Data” to knowledge and improved understanding of the disease.
The disease is known to be profoundly complex, involving multiple tissues and organs systems that result in complex interactions between host and pathogen. The natural history of the disease is also complex, with acute infection that mimics signs of other illnesses and often leading to chronic neurological, immune, and muscoloskeletal dysfunction.
The Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai uses its unique vantage at the nexus of clinical medicine, applied –omics, data science, and digital health to illuminate better understanding, prevention, and treatment of complex diseases.
To learn more about the Institute for Next Generation Healthcare please visit nextgenhealthcare.org
LymeMIND is made possible by generous support from the Cohen Lyme & Tickborne Disease Initiative. Launched in 2015, the Initiative seeks to gather the brightest minds within the research and medical communities to better understand and ultimately stop the rapid spread of tickborne illnesses. It has committed over $60 million to more than 25 research projects across the nation.
© 2018 LymeMIND. All rights reserved.